Completed PHASE3 INTERVENTIONAL 2-arm NCT00157651

Access II - Trial of Warfarin to Prevent Malfunction of Haemodialysis Catheters

A Double-Blind, Placebo Controlled, Randomized Trial of Low-Intensity Adjusted-Dose Warfarin for the Prevention of Mechanical Malfunction of Double-Lumen Haemodialysis Catheters

Sponsor: Hamilton Health Sciences Corporation

Conditions Bleeding End Stage Renal Disease Thrombosis

Interventions placebo warfarin

Updated 5 times since 2017 Last updated: Jun 16, 2008 Started: Feb 28, 1999 Primary completion: Mar 31, 2007 Completion: Mar 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Bleeding and End Stage Renal Disease, this trial is completed. The trial is conducted by Hamilton Health Sciences Corporation and has accumulated 5 data snapshots since 1999. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Feb 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hamilton Health Sciences Corporation

Data source: McMaster University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hamilton, Canada